Atlas Capital Advisors Inc. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Atlas Capital Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 31,944 shares of the company’s stock, valued at approximately $997,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. AQR Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth raised its stake in shares of Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $255,000. Flow Traders U.S. LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $238,000. Finally, Cerity Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 2.9% in the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.2%

Teva Pharmaceutical Industries stock opened at $34.58 on Monday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock has a market capitalization of $39.75 billion, a P/E ratio of 26.00, a PEG ratio of 3.53 and a beta of 0.84. The stock has a 50-day simple moving average of $33.28 and a 200 day simple moving average of $32.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion during the quarter. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on TEVA. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Bank of America lifted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the sale, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the sale, the executive vice president owned 172,184 shares of the company’s stock, valued at $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 421,470 shares of company stock valued at $14,570,945 in the last three months. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.